BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Nov 26, 2025; 17(11): 109287
Published online Nov 26, 2025. doi: 10.4330/wjc.v17.i11.109287
Medium-to-long term outcomes of bioresorbable scaffold treatment in patients with acute coronary syndrome
Jun Li, Xin-Rui Li, Mo-Wei Kong, Jie Zhang
Jun Li, Jie Zhang, Department of Cardiology, Ren’an Hospital, Zhaotong 657000, Yunnan Province, China
Xin-Rui Li, Department of Gastroenterology, Shenyang Red Cross Hospital, Shenyang 110000, Liaoning Province, China
Mo-Wei Kong, Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
Co-first authors: Jun Li and Xin-Rui Li.
Author contributions: Li J and Li XR wrote the manuscript, they contributed equally to this article, they are the co-first authors of this manuscript; Kong MW provided crucial suggestions; Zhang J reviewed and revised the manuscript; and all authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Guiqian International General Hospital, approval No. GI-2023NL-055.
Clinical trial registration statement: This study was not registered on a clinical trial registration platform.
Informed consent statement: This study was conducted in compliance with the requirements of the Ethics Committee and informed consent was obtained from all participating patients.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: The data supporting the findings of this study are available upon request. However, due to confidentiality and ethical considerations, access to the data is restricted. Interested researchers may contact the corresponding author for inquiries regarding data availability.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie Zhang, MD, Department of Cardiology, Ren’an Hospital, No. 9 Weixin Road, Industrial Park, Zhaoyang District, Zhaotong 657000, Yunnan Province, China. 443544378@qq.com
Received: May 13, 2025
Revised: July 2, 2025
Accepted: October 21, 2025
Published online: November 26, 2025
Processing time: 198 Days and 19.8 Hours
Core Tip

Core Tip: This study aimed to investigate the safety and effectiveness of bioresorbable scaffolds (BRS) compared to drug-eluting stents (DES) in patients with intermediate to low-risk acute coronary syndrome. A total of 128 patients were included in the study, with 87 receiving BRS and 114 receiving DES. The patients were followed up for a maximum of 3 years to assess the occurrence of cardiac events and complications. The results showed that the time to reach the composite endpoint of cardiac events was earlier in the BRS group compared to the DES group, although the final number did not differ significantly. BRS demonstrated better compatibility than DES. These findings suggest that BRS may be a viable alternative to DES in patients with intermediate to low-risk acute coronary syndrome, but further research is needed to address the observed complications.